The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 9 of the 30 sources its claims cite were checked for support.
The Human Proteoform Project: Defining the human proteome
Open accessAbstract
An ambitious initiative is proposed to generate a definitive reference set of human proteoforms.
Overview
CoChat Summary
## TL;DR
The paper is a roadmap/proposal for the Human Proteoform Project, arguing that understanding biology and disease requires a comprehensive reference atlas of human proteoforms, not just genome sequence. It proposes a two-pronged strategy: deep proteoform analysis in medically relevant systems and large-scale technology development for proteoform discovery and characterization.
## Key findings
- The authors argue that the human proteome should be defined as the set of all proteoforms expressed by an organism, because proteins from a single gene can vary through genetic variation, alternative splicing, and PTMs.
- They propose an atlas-building strategy centered on two paths: global studies of detectable proteoforms and targeted studies of proteoform families from each human gene.
- The paper gives explicit scale estimates for the project: assuming 5,000 cell types and a depth of 1 million proteoforms in each, the Human Proteoform Atlas would involve about 5 billion measurements of redundant proteoforms; combined with the gene-based approach, it anticipates about 50 million unique (nonredundant) proteoforms with defined quality metrics.
- It notes that current bottom-up proteomics remains limited: the aggregated NCI-60 dataset covers only 12% of the whole encoded proteome, only about 5% of genes had >50% sequence coverage of their protein-coding regions, and detection of alternative splice forms remains very limited (<0.1% of putative novel splice junctions in cancer xenografts).
## Methods
- Not an empirical study; this is a perspective/proposal article laying out a conceptual framework and roadmap for the Human Proteoform Project.
- The proposed design combines cell-based proteoform discovery across defined human cell types with a gene-based targeted approach using affinity reagents to enrich proteoform families.
- The main analysis is argumentative and strategic: it synthesizes existing proteomics limitations, compares top-down and bottom-up approaches, and uses rough scale estimates to motivate technology development and atlas construction.
## Limitations
- The paper states that today’s ability to comprehensively identify proteoforms in complex systems is limited, and that top-down proteomics is powerful but still limited in depth and throughput.
- It explicitly says the project will necessarily focus on capturing the dominant functional proteoform population rather than rare occurrences.
- Evident from the text: the paper does not present new experimental data or validate the proposed atlas; its estimates and goals are forward-looking projections rather than results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
6 Valid · 2 Not valid · 13 Not checked · 14 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“At present, the dominant “bottom-up” paradigm of mass spectrometry (MS)–based proteomics sacrifices information about proteoforms by cleaving proteins into peptides; this is done for a pragmatic reason—it works, as the resultant peptides are generally much easier to identify than their parent intact proteoforms ( 8 , 9 ).”
What the sources say
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic variation, alternative splicing, and posttranslational modification (PTM) work together to create a rich variety of different proteoforms arising from our genes ( Fig. 1 ) ( 3 ).”
What the sources say
- Supportedcites [3] source
In “To the Editor,” the paper says protein complexity arises from allelic variation, alternative RNA splicing, and post-translational modifications. It then defines proteoforms as the different molecular forms of a single gene’s protein product, including forms produced by all three mechanisms (Fig. 1). (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Proteins are the central intermediaries between genotype and phenotype ( 2 – 4 ).”
What the sources say
- Not checked yetcites [2] source
- Supportedcites [3] source
In “To the Editor” (page not specified), the paper links genetic and RNA variation to distinct protein molecules, then says those molecules modulate a wide variety of biological processes. That supports the broad description of proteins as intermediaries between genotype and phenotype. (LLM, conf=0.85)
- Supportedcites [4] source
The Abstract (p. 3) describes proteins as deeply involved in the major processes of life and occupying the space between human genetics and diverse phenotypes. This supports the citing sentence’s paraphrase. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While today’s mass spectrometric platforms are pushing toward detection limits of ~25 copies per cell ( 7 ),”
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
Our copy does address mass-spectrometric detection sensitivity at the per-cell copy-number level, but the only threshold it gives is a project requirement, not a current capability: 'A cell-based Human Proteome Project places a premium on defining and isolating specific cell types prior to analysis with 100 % sequence coverage for proteoforms detected at a copy number of 10 and above' (Discussion > Defining the Proteome of Specific Cell Types). Nowhere in the paper is a '~25 copies per cell' detection limit stated, nor is any figure attributed to 'today's mass spectrometric platforms' current push; the nearby numbers (~10,000 expressed proteins detectable from a single human cell type, ~250,000 detectable proteoforms per cell type, <20 % sequence-space coverage of mainstream technologies) concern protein/proteoform counts and coverage, not copies-per-cell limits. So the direction of the claim (MS sensitivity approaching low copy numbers per cell) is in the source, but the specific ~25 value and its framing as present-day capability are not supported. (LLM, conf=0.62)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The depth of proteoform analysis obtained depends on the detection sensitivity of the technology used:”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 35 claims and to verify the 21 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A full characterization of protein variability also remains a major technical challenge, since the approximately 20,300 human coding genes can produce hundreds of thousands of protein variants through alternative splicing and posttranslational modification (PTM) (129, 130).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [129]
Experimental — accuracy not yet measured
Citations
Cites
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813 · cited 2×
“Prior initiatives such as those describing first drafts of the human proteome in 2014 (33, 34) and ongoing work under the aegis of the Human Protein Atlas and the Human Proteome Project (35) have accomplished a great deal over the past several years, and the Human Proteome Organization has called for the community to…”
MethodEcosystem as Structure: An Actionable Construct for Strategy
Adner, R. (2017) · Journal of Management · doi:10.1177/0149206316678451 · Cited by 2,600
Mass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334 · cited 1×
“NEW TECHNOLOGIES At present, the dominant “bottom-up” paradigm of mass spectrometry (MS)–based proteomics sacrifices information about proteoforms by cleaving proteins into peptides; this is done for a pragmatic reason—it works, as the resultant peptides are generally much easier to identify than their parent intact p…”
BackgroundRegev, A., Teichmann, S. A., Lander, E. S., Amit, I., Benoist, C., Birney, E., Bodenmiller, B., Campbell, P., Carninci, P., Clatworthy, M., et al. (2017) · eLife · doi:10.7554/elife.27041 · Cited by 2,232
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820 · cited 1×
“Prior initiatives such as those describing first drafts of the human proteome in 2014 (33, 34) and ongoing work under the aegis of the Human Protein Atlas and the Human Proteome Project (35) have accomplished a great deal over the past several years, and the Human Proteome Organization has called for the community to…”
MethodA vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752 · cited 3×
“Proteins are primary effectors of function in biology, and thus, complete knowledge of their structure and behavior is fundamental to deciphering function in basic and translational research (2).”
BackgroundMethodProteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Proteoform: a single term describing protein complexity
The Consortium for Top Down Proteomics, Smith, L. M., & Kelleher, N. L. (2013) · Nature Methods · doi:10.1038/nmeth.2369 · Cited by 1,528
Self-citationProtein Analysis by Shotgun/Bottom-up Proteomics
Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C., & Yates, J. R. (2013) · Chemical Reviews · doi:10.1021/cr3003533 · Cited by 1,491
Regev, A., Teichmann, S. A., Lander, E. S., Amit, I., Benoist, C. O., Birney, E., Bodenmiller, B., & Campbell, P. J. (2017) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-162597 · Cited by 1,399
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Zhang, H., Liu, T., Zhang, Z., Payne, S. H., Zhang, B., McDermott, J. E., Zhou, J.-Y., Petyuk, V. A., Chen, L., Ray, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.069 · Cited by 1,029
How many human proteoforms are there?
Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., Costello, C. E., Cravatt, B. F., Fenselau, C., Garcia, B. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2576 · Cited by 907
Self-citationBudnik, B., Levy, E., Harmange, G., & Slavov, N. (2018) · Genome Biology · doi:10.1186/s13059-018-1547-5 · Cited by 832
Reproducibility crisis: Blame it on the antibodies
Baker, M. (2015) · Nature · doi:10.1038/521274a · Cited by 830
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799
Mapping intact protein isoforms in discovery mode using top-down proteomics
Tran, J. C., Zamdborg, L., Ahlf, D. R., Lee, J. E., Catherman, A. D., Durbin, K. R., Tipton, J. D., Vellaichamy, A., Kellie, J. F., Li, M., et al. (2011) · Nature · doi:10.1038/nature10575 · Cited by 665
Self-citationThe human body at cellular resolution: the NIH Human Biomolecular Atlas Program
HuBMAP Consortium, Writing Group, Snyder, M. P., Lin, S., Posgai, A., Atkinson, M., Regev, A., Rood, J., Rozenblatt-Rosen, O., Gaffney, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1629-x · Cited by 595
Electrical recognition of the twenty proteinogenic amino acids using an aerolysin nanopore
Ouldali, H., Sarthak, K., Ensslen, T., Piguet, F., Manivet, P., Pelta, J., Behrends, J. C., Aksimentiev, A., & Oukhaled, A. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0345-2 · Cited by 474 · cited 1×
“Similarly, single-molecule MS (18–20), nanopore sequencing (21, 22), cryoelectron microscopy and visual proteomics (23, 24), single-cell proteomics (25–29), single-molecule protein arrays (30, 31), and other ideas yet to be conceived need to be encouraged, supported, and developed to advance proteoform biology.”
BackgroundPaving the way to single-molecule protein sequencing
Restrepo-Pérez, L., Joo, C., & Dekker, C. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0236-6 · Cited by 396 · cited 1×
“Similarly, single-molecule MS (18–20), nanopore sequencing (21, 22), cryoelectron microscopy and visual proteomics (23, 24), single-cell proteomics (25–29), single-molecule protein arrays (30, 31), and other ideas yet to be conceived need to be encouraged, supported, and developed to advance proteoform biology.”
BackgroundValkokari, K. (2015) · Technology Innovation Management Review · doi:10.22215/timreview/919 · Cited by 353 · cited 1×
“Within the emergent proteomics ecosystem that we envisage, three categories of organizations can be identified—those focused on creating new knowledge (universities and research institutes), those creating new value for customers (instrument, biopharma, and diagnostics companies), and those providing financial and oth…”
BackgroundProteoforms as the next proteomics currency
Smith, L. M., & Kelleher, N. L. (2018) · Science · doi:10.1126/science.aat1884 · Cited by 322 · cited 2×
“Top-down proteomics, in contrast, analyzes the entire intact proteoform and is the most powerful proteoform-level analysis technology in existence, providing knowledge regarding RNA isoform translation and combinatorial PTMs, but is limited in depth and throughput (4, 6).”
BackgroundSelf-citationZhu, Y., Clair, G., Chrisler, W. B., Shen, Y., Zhao, R., Shukla, A. K., Moore, R. J., Misra, R. S., Pryhuber, G. S., Smith, R. D., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802843 · Cited by 259
Highly parallel single-molecule identification of proteins in zeptomole-scale mixtures
Swaminathan, J., Boulgakov, A. A., Hernandez, E. T., Bardo, A. M., Bachman, J. L., Marotta, J., Johnson, A. M., Anslyn, E. V., & Marcotte, E. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4278 · Cited by 218 · cited 1×
“Similarly, single-molecule MS (18–20), nanopore sequencing (21, 22), cryoelectron microscopy and visual proteomics (23, 24), single-cell proteomics (25–29), single-molecule protein arrays (30, 31), and other ideas yet to be conceived need to be encouraged, supported, and developed to advance proteoform biology.”
BackgroundTop-Down Proteomics: Ready for Prime Time?
Chen, B., Brown, K. A., Lin, Z., & Ge, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04747 · Cited by 210
Self-citationA high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Kafader, J. O., Melani, R. D., Durbin, K. R., Ikwuagwu, B., Early, B. P., Fellers, R. T., Beu, S. C., Zabrouskov, V., Makarov, A. A., Maze, J. T., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0764-5 · Cited by 197
Self-citationZhang, J., Guy, M. J., Norman, H. S., Chen, Y.-C., Xu, Q., Dong, X., Guner, H., Wang, S., Kohmoto, T., Young, K. H., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200258m · Cited by 194
Self-citationInduced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Ultrasensitive Detection of Attomolar Protein Concentrations by Dropcast Single Molecule Assays
Wu, C., Garden, P. M., & Walt, D. R. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04331 · Cited by 176 · cited 1×
“Similarly, single-molecule MS (18–20), nanopore sequencing (21, 22), cryoelectron microscopy and visual proteomics (23, 24), single-cell proteomics (25–29), single-molecule protein arrays (30, 31), and other ideas yet to be conceived need to be encouraged, supported, and developed to advance proteoform biology.”
BackgroundLévesque, S., Dufresne, P. J., Soualhine, H., Domingo, M.-C., Bekal, S., Lefebvre, B., & Tremblay, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144878 · Cited by 172
Single-cell protein analysis by mass spectrometry
Slavov, N. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.04.018 · Cited by 164
Ansong, C., Wu, S., Meng, D., Liu, X., Brewer, H. M., Deatherage Kaiser, B. L., Nakayasu, E. S., Cort, J. R., Pevzner, P., Smith, R. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221210110 · Cited by 157
Self-citationVisual proteomics of the human pathogen Leptospira interrogans
Beck, M., Malmström, J. A., Lange, V., Schmidt, A., Deutsch, E. W., & Aebersold, R. (2009) · Nature Methods · doi:10.1038/nmeth.1390 · Cited by 156 · cited 1×
“Similarly, single-molecule MS (18–20), nanopore sequencing (21, 22), cryoelectron microscopy and visual proteomics (23, 24), single-cell proteomics (25–29), single-molecule protein arrays (30, 31), and other ideas yet to be conceived need to be encouraged, supported, and developed to advance proteoform biology.”
BackgroundThe most popular genes in the human genome
Dolgin, E. (2017) · Nature · doi:10.1038/d41586-017-07291-9 · Cited by 142
Transformative Opportunities for Single-Cell Proteomics
Specht, H., & Slavov, N. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00257 · Cited by 137
Neutral mass spectrometry of virus capsids above 100 megadaltons with nanomechanical resonators
Domínguez-Medina, S., Fostner, S., Defoort, M., Sansa, M., Stark, A.-K., Halim, M. A., Vernhes, É., Gély, M., Jourdan, G., Alava, T., et al. (2018) · Science · doi:10.1126/science.aat6457 · Cited by 130
Ruggles, K. V., Tang, Z., Wang, X., Grover, H., Askenazi, M., Teubl, J., Cao, S., McLellan, M. D., Clauser, K. R., Tabb, D. L., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.056226 · Cited by 119
A five-level classification system for proteoform identifications
Smith, L. M., Thomas, P. M., Shortreed, M. R., Schaffer, L. V., Fellers, R. T., LeDuc, R. D., Tucholski, T., Ge, Y., Agar, J. N., Anderson, L. C., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0573-x · Cited by 90
Self-citationMeasurement of Individual Ions Sharply Increases the Resolution of Orbitrap Mass Spectra of Proteins
Kafader, J. O., Melani, R. D., Senko, M. W., Makarov, A. A., Kelleher, N. L., & Compton, P. D. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04519 · Cited by 87
Self-citationZhou, M., Uwugiaren, N., Williams, S. M., Moore, R. J., Zhao, R., Goodlett, D., Dapic, I., Paša-Tolić, L., & Zhu, Y. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00467 · Cited by 62
Self-citationDe Novo Structural Pattern Mining in Cellular Electron Cryotomograms
Xu, M., Singla, J., Tocheva, E. I., Chang, Y., Stevens, R. C., Jensen, G. J., & Alber, F. (2019) · Structure · doi:10.1016/j.str.2019.01.005 · Cited by 60
A Cell-Based Approach to the Human Proteome Project
Kelleher, N. L. (2012) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-012-0469-9 · Cited by 55 · cited 2×
“The depth of proteoform analysis obtained depends on the detection sensitivity of the technology used: While today’s mass spectrometric platforms are pushing toward detection limits of ~25 copies per cell (7), aggressive technology investment is needed to further develop these platforms and to develop new approaches a…”
BackgroundMethodSelf-citationProForma: A Standard Proteoform Notation
LeDuc, R. D., Schwämmle, V., Shortreed, M. R., Cesnik, A. J., Solntsev, S. K., Shaw, J., Martin, M. J., Vizcaíno, J. A., Alpi, E., Danis, P. O., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00851 · Cited by 52
Self-citationGenomics Research: World Survey of Public Funding
Pohlhaus, J. R., & Cook-Deegan, R. M. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-472 · Cited by 38 · cited 1×
“This will require substantial funding; for comparison, genomics research worldwide was publicly funded at about $3B per year from 2003 to 2006, with the United States contributing about 35% of this (44).”
BackgroundKellie, J. F., Tran, J. C., Jian, W., Jones, B. R., Mehl, J. T., Ge, Y., Henion, J. D., & Bateman, K. P. (2020) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00270 · Cited by 30 · cited 1×
“There has also been an industry-led call from several pharmaceutical companies underscoring the need for major improvements in proteoform measurement (37).”
BackgroundSelf-citationThe Human Proteoform Project: A Plan to Define the Human ProteomePreprint
Smith, L. M., Agar, J. N., Chamot‐Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša‐Tolić, L., Tsybin, Y. O., & Kelleher, N. L. (2020) · Preprints.org · doi:10.20944/preprints202010.0368.v1 · Cited by 16 · cited 2×
“Five important clinical areas of interest are depicted and serve as examples where proteoforms have been identified and linked to the progression of human disease; they are discussed at length in an extended preprint version of this Perspective (32).”
BackgroundMethodSelf-citationTargeting Phosphotyrosine in Native Proteins with Conditional, Bispecific Antibody Traps
Zhou, X. X., Bracken, C. J., Zhang, K., Zhou, J., Mou, Y., Wang, L., Cheng, Y., Leung, K., & Wells, J. A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c08458 · Cited by 13
What is the human genome worth?
Drake, N. (2011) · Nature · doi:10.1038/news.2011.281 · Cited by 10
Cited by
Novel Strategies to Address the Challenges in Top-Down Proteomics
Melby, J. A., Roberts, D. S., Larson, E. J., Brown, K. A., Bayne, E. F., Jin, S., & Ge, Y. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00099 · Cited by 190
Self-citationConnecting aging biology and inflammation in the omics era
Walker, K. A., Basisty, N., Wilson, D. M., & Ferrucci, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158448 · Cited by 189
“A full characterization of protein variability also remains a major technical challenge, since the approximately 20,300 human coding genes can produce hundreds of thousands of protein variants through alternative splicing and posttranslational modification (PTM) (129, 130).”
BackgroundGlobal detection of human variants and isoforms by deep proteome sequencing
Sinitcyn, P., Richards, A. L., Weatheritt, R. J., Brademan, D. R., Marx, H., Shishkova, E., Meyer, J. G., Hebert, A. S., Westphall, M. S., Blencowe, B. J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01714-x · Cited by 182
“Thus, sequence coverage in a proteomics experiment is generally insufficient to fully characterize all protein states present within a sample 21,22 .”
BackgroundRoberts, D. S., Loo, J. A., Tsybin, Y. O., Liu, X., Wu, S., Chamot-Rooke, J., Agar, J. N., Paša-Tolić, L., Smith, L. M., & Ge, Y. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00318-2 · Cited by 161
Self-citationThe Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells
Melani, R. D., Gerbasi, V. R., Anderson, L. C., Sikora, J. W., Toby, T. K., Hutton, J. E., Butcher, D. S., Negrão, F., Seckler, H. S., Srzentić, K., et al. (2022) · Science · doi:10.1126/science.aaz5284 · Cited by 140
Self-citation
Metadata
- Authors
- Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša-Tolić, L., Tsybin, Y. O., Kelleher, N. L., & The Consortium for Top-Down Proteomics
- Affiliations
- University of Wisconsin–Madison (US)
- Northeastern University (US)
- Department of Structural Biology and Chemistry, Institut Pasteur, CNRS, Paris, France.
- Consortium for Top-Down Proteomics, Cambridge, MA, USA.
- University of California, Los Angeles (US)
- Pacific Northwest National Laboratory, Richland, WA, USA.
- Spectroswiss (Switzerland) (CH)
- Northwestern University (US)
- Corresponding author
- Kelleher, Neil L.
- ORCID
- Venue
- Science Advances
- Published
- 2021-11-12
- Volume
- 7
- Issue
- 46
- Pages
- eabk0734-eabk0734
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC8589312
- OpenAlex
- W3212853007
- Semantic Scholar
- ec7918066a2371daeda68b271a36d2b5dc582e6d
- Cited by
- 242
- References
- 49
- Citations by year
- 2026: 43 · 2025: 51 · 2024: 51 · 2023: 52 · 2022: 39 · 2021: 6
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- U.S. Department of Energy (DE-AC05–76RL01830, 76RL01830, AC05-76RL01830, DE-AC05?, DEFC0202ER63421, FC02-02ER63421)
- Centre National de la Recherche Scientifique
- National Institutes of Health (DE-FC02-02ER63421, UL1TR001422, HL096971, DE-AC05-76RL01830)
- Office of Science (02ER63421, DEFC0202ER63421, DE‐AC05‐76 RL01830)
- National Heart, Lung, and Blood Institute (R01HL096971)
- National Cancer Institute (UG3CA256959)
- National Institute of General Medical Sciences (P41GM108569, GM117058, R01GM103479, GM125085, R01GM125085, R01GM117058, R35GM126914)
- National Center for Advancing Translational Sciences
- Biological and Environmental Research (DE-AC05-76 RL01830, DE‐FC02‐02ER63421, AC05-76RL01830, 76RL01830)
- Common Fund
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Keywords
- human proteome, proteoforms, post-translational modification, genetic polymorphism, disease research, proteomics technologies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.